Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection

Guidelines for the screening, care and treatment of persons with hepatitis C infection

WHO has  just published its updated version of the guidelines for the screening, care and treatment of persons with hepatitis C infection complement existing guidance on the prevention of transmission of bloodborne viruses, including HCV. They are intended for policy-makers, government officials, and others working in low- and middle-income countries who are developing programmes for the screening, care and treatment of persons with HCV infection.

Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection, World health Organization, WHO, Hepatitis, HCV

Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection, World health Organization, WHO, Hepatitis, HCV

The field of HCV therapeutics continues to evolve rapidly and, since the World Health Organization (WHO) issued its first Guidelines for the screening, care and treatment of persons with hepatitis C infection in 2014, several new medicines have been approved by at least one stringent regulatory authority. These medicines, called direct-acting antivirals (DAAs), are transforming the treatment of HCV, enabling regimens that can be administered orally, are of shorter duration, result in cure rates higher than 90%, and are associated with fewer serious adverse events than the previous interferon- containing regimens. WHO is updating its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines.

The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV genotype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014.

 

In developing the recommendations, the Guidelines Development Group considered the evidence as well as the characteristics of each regimen, such as pill burden, frequency of drug–drug interactions, and whether they required interferon or ribavirin. Based on these considerations, preferred and alternative regimens were selected for each genotype. Decision-makers will then be able to choose from these options based on the price and availability of the medicines and the endemic HCV genotypes in their countries. To support decision-making, clinical considerations such as treatment prioritization, drug–drug interactions, monitoring for treatment response and adverse reactions, treatment in pregnancy and in those with coinfection are also covered in the guidelines, in addition to treatment considerations for specific populations.

 

for downloading the guideline please click on Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection

Join our mailing list to receive our weekly updates